JPRN-jRCTs031230118
Recruiting
未知
An open-label, single-arm study to investigate the efficacy of Favipiravir on Lassa Fever for Post Exposure Prophylaxis - FavLap
Morioka Shinichiro0 sites5 target enrollmentDecember 1, 2023
Conditionsassa fever
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- assa fever
- Sponsor
- Morioka Shinichiro
- Enrollment
- 5
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\)Has given written consent to participate in the study
- •2\)18 years of age or older at the time consent is given
- •3\)Has a skin injury from a sharp instrument contaminated (or suspicious to be so) with Lassa virus.
- •4\)Whose the mucous membranes or damaged skin has been contacted with a sample contaminated with Lassa virus.
- •5\)Contacted with a patient with Lassa fever (or who is suspicious to be so) within a confined space without wearing appropriate protective equipment.
- •6\)Performed emergent intervention such as cardiopulmonary resuscitation without wearing appropriate protective equipment.
- •7\)Other situation in relation to 1\)\-4\) above, those considered to be adequate for post exposure prophylaxis by principle/sub investigator.
Exclusion Criteria
- •1\) Prengant patient
- •2\) Those who are breast\-feeding and cannot promise to stop breast\-feeding during and for 7 days after the end of administration
- •3\) Unable to commit to using an effective contraceptive method during treatment and for 14 days after completion of treatment for women and during treatment and for 7 days after completion of treatment for men
- •4\) Women who cannot commit to not donating eggs during treatment and for 14 days after completion of treatment, or men who cannot commit to not donating sperm for reproductive purposes during treatment and for 7 days after completion of treatment
- •5\) Those who cannot promise not to have sexual intercourse with pregnant women during and for 7 days after completion of administration
- •6\) Persons with a history of severe hypersensitivity to the ingredients of Favipiravir
- •7\) More than 22 days after exposure
- •8\) Those that have already developed Lassa fever
- •9\) Judged illegible to participate in the study by the principal investigator or sub\-investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A study to understand disease biology and to test the effect and safety of inhaled nemiralisib in adult patients with APDSEUCTR2015-004876-31-GBGlaxoSmithKline Research & Development Ltd20
Recruiting
Phase 1
An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neonates and infants under 6 months of age with confirmed complicated influenza infection.CTIS2024-510663-34-00Glaxosmithkline Research & Development Limited12
Active, not recruiting
Phase 1
An open label, single arm study to evaluate the pharmacokinetics, safety and tolerability of intravenous (IV) zanamivir in hospitalised neonates and infants under 6 months of age with confirmed influenza infectioEUCTR2019-001588-63-NLGlaxoSmithKline Research & Development Limited12
Active, not recruiting
Phase 1
An open label, single arm study to evaluate the pharmacokinetics, safety and tolerability of intravenous (IV) zanamivir in hospitalised neonates and infants under 6 months of age with confirmed influenza infectioInfluenzaTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2019-001588-63-PLGlaxoSmithKline Research & Development Limited12
Not yet recruiting
Phase 2
An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous |(IV) zanamivir in neonates and infants under 6 months of age with confirmed complicated influenza infectioNL-OMON50842GlaxoSmithKline3